Insamo

Operator of a biotechnology platform intended to pioneer the discovery of membrane-permeable and orally available cyclic peptides with antibody-like binding affinity. The company’s platform develops molecular biology and parallel synthetic chemistry to rapidly identify preclinical candidates that exhibit favorable pharmacological properties, enabling health professionals to enhance patient care by replacing injected or infused biologics with easily administered oral cyclic-peptide formulations.